Investigative Safety, Clinical Activity of CAR-T in Metastatic Colorectal Cancer
By Benjamin L. Schlechter, MD - Last Updated: March 19, 2025Benjamin L. Schlechter, MD, of Dana-Farber Cancer Institute, discusses phase 1 dose escalation study of a novel coupled CAR-T therapy, GCC19CART, for patients with metastatic colorectal cancer.
Advertisement
He shares key findings regarding safety and tolerability, including preliminary efficacy results.
Advertisement
Related Posts
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
Sotorasib with panitumumab and FOLFIRI has shown promising long-term efficacy results in pretreated KRAS G12C–mutated ...
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.